Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kaletra Switch Therapy in ARV Experienced Patients
NCT00648999Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2003
- Primary completion
- Dec 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of lopinavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Quality of Life at Week 48 and CD4 Cell Count at Week 48. Started Nov 2003; status: completed.
02
Drugs
lopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00648999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00648999.